Global Infectious Vaccines Partnering Terms and Agreements 2010 to 2017: Deal trends, players and financials

Publisher Name :
Date: 01-Apr-2017
No. of pages: 457
Inquire Before Buying

"Delivery of this report will take 1-3 days after purchase."

The Global Infectious Vaccines Partnering Terms and Agreements 2010 to 2017: Deal trends, players and financials report provides comprehensive understanding and unprecedented access to the infectious vaccines partnering deals and agreements entered into by the worlds leading healthcare companies

The Global Infectious Vaccines Partnering Terms and Agreements 2010 to 2017: Deal trends, players and financials report provides a detailed understanding and analysis of how and why companies enter infectious vaccines partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors vaccine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. The report also includes adjuvant deals and alliances.

This report provides details of the latest infectious vaccines agreements announced in the healthcare sectors.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all infectious vaccines partnering deals announced since January 2010, including financial terms where available, including over 600 links to online deal records of actual infectious vaccines partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of Infectious Vaccines dealmaking and business activities.

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Infectious Vaccines dealmaking since 2010, including details of average headline, upfront, milestone and royalty terms. Infectious Vaccines deals since 2010. Deals are listed by headline value, signed by big pharma, most active Infectious Vaccines dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 3 provides a review of the leading Infectious Vaccines deals since 2010. Deals are listed by headline value, signed by big pharma, most active Infectious Vaccines dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in Infectious Vaccines dealmaking with a brief summary followed by a comprehensive listing of Infectious Vaccines deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of Infectious Vaccines partnering deals signed and announced since Jan to 2010, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of Infectious Vaccines partnering deals signed and announced since Jan to 2010. The chapter is organized by specific Infectious Vaccines technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided organized by Infectious Vaccines partnering company A-Z, deal type definitions and Infectious Vaccines partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. The report also includes numerous tables and figures that illustrate the trends and activities in Infectious Vaccines partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Infectious Vaccines technologies and products.

Report scope

Global Infectious Vaccines Partnering Terms and Agreements 2010 to 2017: Deal trends, players and financials is intended to provide the reader with an in-depth understanding and access to infectious vaccines trends and structure of deals entered into by leading companies worldwide.Global Infectious Vaccines Partnering Terms and Agreements 2010 to 2016: Deal trends, players and financials includes:

Trends in infectious vaccines dealmaking in the biopharma industry since 2010

Analysis of infectious vaccines deal structure

Access to headline, upfront, milestone and royalty data

Access to over 600 infectious vaccines deal records

Identify the most active infectious vaccine dealmakers since 2010

The leading infectious vaccines deals by value since 2010

Includes adjuvant deals and alliances since 2010

In Global Infectious Vaccines Partnering Terms and Agreements 2010 to 2017: Deal trends, players and financials, the available deals are listed by:

Company A-Z

Headline value

Stage of development at signing

Deal component type

Specific infectious therapy target

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Infectious Vaccines Partnering Terms and Agreements 2010 to 2017: Deal trends, players and financials report provides comprehensive access to available deals and contract documents for over 500 infectious vaccines deals. Analyzing actual contract agreements allows assessment of the following:

What are the precise rights granted or optioned?

What is actually granted by the agreement to the partner company?

What exclusivity is granted?

What is the payment structure for the deal?

How aresalesand payments audited?

What is the deal term?

How are the key terms of the agreement defined?

How are IPRs handled and owned?

Who is responsible for commercialization?

Who is responsible for development, supply, and manufacture?

How is confidentiality and publication managed?

How are disputes to be resolved?

Under what conditions can the deal be terminated?

What happens when there is a change of ownership?

What sublicensing and subcontracting provisions have been agreed?

Which boilerplate clauses does the company insist upon?

Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

Which jurisdiction does the company insist upon for agreement law?

Infectious Vaccines Partnering Terms and Agreements provides the reader with the following key benefits:

In-depth understanding of infectious vaccines deal trends since 2010

Access infectious vaccines deal headline, upfront, milestone and royalty data

Analysis of the structure of infectious vaccines agreements with numerous real life case studies

Comprehensive access to over 600 links to actual infectious vaccines deals entered into by the world's biopharma companies, together with real world clause examples

Identify leading infectious vaccines deals by value since 2010

Identify the most active infectious vaccines dealmakers since 2010

Insight into the terms included in infectious vaccines agreement, together with real world clause examples

Understand the key deal terms companies have agreed in previous deals

Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Global Infectious Vaccines Partnering Terms and Agreements 2010 to 2017: Deal trends, players and financials

Table of Contents
Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Infectious Vaccines dealmaking
2.1. Introduction
2.2. Infectious Vaccines partnering over the years
2.3. Most active Infectious Vaccines dealmakers
2.4. Infectious Vaccines partnering by deal type
2.5. Infectious Vaccines partnering by therapy area
2.6. Deal terms for Infectious Vaccines partnering
2.6.1 Infectious Vaccines partnering headline values
2.6.2 Infectious Vaccines deal upfront payments
2.6.3 Infectious Vaccines deal milestone payments
2.6.4 Infectious Vaccines royalty rates

Chapter 3 - Leading Infectious Vaccines deals
3.1. Introduction
3.2. Top Infectious Vaccines deals by value

Chapter 4 - Most active Infectious Vaccines dealmakers
4.1. Introduction
4.2. Most active Infectious Vaccines dealmakers
4.3. Most active Infectious Vaccines partnering company profiles

Chapter 5 - Infectious Vaccines contracts dealmaking directory
5.1. Introduction
5.2. Infectious Vaccines contracts dealmaking directory

Chapter 6 - Infectious Vaccines dealmaking by technology type

Chapter 7 - Partnering resource center
7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking

Appendices

Appendix 1 - Infectious Vaccines deals by company A-Z
Appendix 2 - Infectious Vaccines deals by stage of development
Discovery
Preclinical
Phase I
Phase II
Phase III
Regulatory
Marketed
Formulation
Appendix 3 - Infectious Vaccines deals by deal type
Asset purchase
Assignment
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Co-promotion
CRADA
Development
Distribution
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Manufacturing
Marketing
Option
Promotion
Research
Settlement
Spin out
Sub-license
Supply
Technology transfer
Termination
Appendix 4 - Infectious Vaccines deals by therapy area
Appendix 5 - Deal type definitions
About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from Current Partnering
Table of figures
Figure 1: Infectious Vaccines partnering since 2010
Figure 2: Active Infectious Vaccines dealmaking activity since 2010
Figure 3: Infectious Vaccines partnering by deal type since 2010
Figure 4: Infectious Vaccines partnering by disease type since 2010
Figure 5: Infectious Vaccines deals with a headline value
Figure 6: Infectious Vaccines deals with an upfront value
Figure 7: Infectious Vaccines deals with a milestone value
Figure 8: Infectious Vaccines deals with a royalty rate value
Figure 9: Top Infectious Vaccines deals by value since 2010
Figure 10: Most active Infectious Vaccines dealmakers since 2010
Figure 11: Online partnering resources
Figure 12: Forthcoming partnering events
  • Renewable Energy Sources Needs To Boost Global Microgrids Market
    The global market for microgrid was worth US$13.3 billion in 2015, and is anticipated to touch an estimate of US$35.2 billion by 2020. Dealers in the market for microgrids are incessantly improving the network hosting capability for renewable energy resources to excerpt an extreme amount from it, in addition to commercialization of classically costly renewable […]
  • Manufacturing Trends In The Coming Days
    The manufacturing industry may be encountering some breezes, but it is irrefutably in the middle of a technological revival that is altering the appearance, structures, and practices of the modern factory. Notwithstanding the jeopardies and in spite of recent history industrial manufacturing enterprises cannot afford to disregard these developments. Few of the trends to look […]
  • Top 10 Emerging Technologies
    The World Economic Forum (WEF) and Scientific American lately unveiled the major technological innovation list of the top ten emerging technologies. This list emphasizes on the technological developments which have the supremacy to transform industries, protect the planet, and improve lives. It also presents an opening to discuss any societal, human, economic or environmental jeopardies […]
  • Global Biosimilars Market To Be Led By Novartis by 2020
    Biologics, which are typically inoculated or injected, are formed in living entities, making them more challenging and costly to manufacture than the usual pills contrived from chemicals. Observing that mock-ups are mostly identical to the prototypes has also modelled specific scientific and regulatory tasks. But the US FDA and European supervisors lately have acknowledged new […]
  • Global Thyroid Gland Disorder Treatment Market To Grow Steadily
    The global thyroid gland disorder treatment market was worth US$1.8 billion in 2014 and is projected to reach a market value of US$2.4 billion in 2023 intensifying at a CAGR of 3.1% from 2015 to 2023.  The thyroid gland produces thyroid hormones that control some of the most essential functions in the human body such as stimulating […]
  • United States Ampicillin Market Report 2017
    Published: 19-Jun-2017        Price: US 3800 Onwards        Pages: 100
    In this report, the United States Ampicillin market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report splits the United States market into seven regions: - The West - Southwest - The Middle Atlantic - New England - The South - The Midwest with sales (volume), revenue (value), market share and growth rate of Ampic......
  • EMEA (Europe, Middle East and Africa) Ganciclovir Market Report 2017
    Published: 15-Jun-2017        Price: US 4000 Onwards        Pages: 103
    In this report, the EMEA Ganciclovir market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (K Pcs), revenue (Million USD), market share and growth rate of Ganciclovir for these regions, from 2012 to 2022 (forecast) - Europe: Germany, France, UK, Russia, Italy and Benelux; - Middle E......
  • Global Herpes Treatment Market 2017-2021
    Published: 14-Jun-2017        Price: US 3500 Onwards        Pages: 82
    Herpesviruses belong to double-stranded DNA viruses, which are responsible for a large number of diseases in humans and animals. There are eight types of human herpesvirus (HHV) that affects humans. Among these, herpes simplex virus (HSV) and varicella-zoster virus (VZV) are the two most commonly found HHVs that causes severe infections in humans. HSV is further segmented into oral herpes and genital herpes. The analysts forecast global herpes treatment market to grow at a CAGR of 12.......
  • Global Clotrimazole Market Professional Survey Report 2017
    Published: 14-Jun-2017        Price: US 3500 Onwards        Pages: 113
    This report studies Clotrimazole in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022. This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering - Bayer - Erregierre - F.I.S. - Amoli Organics - CordenPharma......
  • Global Ampicillin Sales Market Report 2017
    Published: 13-Jun-2017        Price: US 4000 Onwards        Pages: 105
    In this report, the global Ampicillin market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split global into several key Regions, with sales (K MT), revenue (Million USD), market share and growth rate of Ampicillin for these regions, from 2012 to 2022 (forecast), covering - United States - China - Europe - Japan - Southeas......
  • Burkholderia pseudomallei Infections (Melioidosis) - Pipeline Review, H1 2017
    Published: 23-May-2017        Price: US 2000 Onwards        Pages: 52
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Burkholderia pseudomallei Infections (Melioidosis) - Pipeline Review, H1 2017, provides an overview of the Burkholderia pseudomallei Infections (Melioidosis) (Infectious Disease) pipeline landscape.Burkholderia pseudomallei are a gram negative, bipolar, aerobic, motile rod-shaped soil dwelling bacterium. The bacterium can infect both animals and humans through direct contact via inhalation, ingestion, or open ......
  • Escherichia coli Infections - Pipeline Review, H1 2017
    Published: 23-May-2017        Price: US 2000 Onwards        Pages: 152
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Escherichia coli Infections - Pipeline Review, H1 2017, provides an overview of the Escherichia coli Infections (Infectious Disease) pipeline landscape.Escherichia coli (E. coli) bacteria normally live in the intestines of healthy people and animals. Escherichia coli infections are caused by coming into contact with the feces, or stool, of humans or animals or drink water or eat food that has been contaminated......
  • Tularaemia - Pipeline Review, H1 2017
    Published: 23-May-2017        Price: US 2000 Onwards        Pages: 68
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Tularaemia - Pipeline Review, H1 2017, provides an overview of the Tularaemia (Infectious Disease) pipeline landscape.Tularaemia is an infection caused due to a bacterium called Francisella tularensis. Humans become infected mainly through the bite of arthropods, particularly ticks and mosquitoes, and through the skin, conjunctival sac or oropharyngeal mucosa, by direct contact with infected animals or animal ......
  • Diphtheria - Pipeline Review, H1 2017
    Published: 23-May-2017        Price: US 2000 Onwards        Pages: 68
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diphtheria - Pipeline Review, H1 2017, provides an overview of the Diphtheria (Infectious Disease) pipeline landscape.Diphtheria is a bacterial infection that affects the membranes of the throat and nose. If left untreated, diphtheria can cause severe damage to kidneys, nervous system, and heart. Symptoms include sore throat and hoarseness, swollen glands (enlarged lymph nodes) in neck, nasal discharge, fever ......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs